Theravance Biopharma (NASDAQ:TBPH) Shares Cross Below 200-Day Moving Average - Here's What Happened

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.77 and traded as low as $8.56. Theravance Biopharma shares last traded at $8.80, with a volume of 102,008 shares changing hands.

Wall Street Analyst Weigh In

TBPH has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partnrs downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 6th. StockNews.com cut Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, August 10th. Leerink Partners downgraded Theravance Biopharma from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. Finally, TD Cowen decreased their target price on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $13.75.

Theravance Biopharma Price Performance

The company has a 50 day simple moving average of $8.18 and a 200-day simple moving average of $8.77. The stock has a market capitalization of $430.50 million, a P/E ratio of -9.57 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.25). The firm had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. As a group, equities analysts forecast that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Insider Activity

In other Theravance Biopharma news, major shareholder Eli Samaha acquired 999,800 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now owns 9,511,150 shares of the company's stock, valued at approximately $74,186,970. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC bought a new stake in shares of Theravance Biopharma during the second quarter valued at about $108,000. XTX Topco Ltd purchased a new stake in Theravance Biopharma in the 2nd quarter worth approximately $129,000. State Board of Administration of Florida Retirement System boosted its holdings in Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company's stock valued at $203,000 after purchasing an additional 4,990 shares during the period. BNP Paribas Financial Markets grew its position in shares of Theravance Biopharma by 30.7% during the 1st quarter. BNP Paribas Financial Markets now owns 33,458 shares of the biopharmaceutical company's stock valued at $300,000 after purchasing an additional 7,851 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Theravance Biopharma during the 2nd quarter valued at $286,000. Institutional investors own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.